A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
Condition: Juvenile Idiopathic Arthritis Interventions: Biological: CNTO 148 (Golimumab); Biological: CNTO 148 (golimumab) or placebo Sponsors: Centocor, Inc.; Schering-Plough (Ireland) Company Recruiting - verified August 2011